학술논문
Albumin-based drug delivery: harnessing nature to cure disease.
Document Type
Academic Journal
Author
Larsen MT; Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark.; Kuhlmann M; Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark.; Hvam ML; Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark.; Howard KA; Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark.
Source
Publisher: River Publishers Country of Publication: Denmark NLM ID: 101624707 Publication Model: eCollection Cited Medium: Print ISSN: 2052-8426 (Print) Linking ISSN: 20528426 NLM ISO Abbreviation: Mol Cell Ther Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2052-8426
Abstract
The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic levels, however, challenges such as rapid renal clearance, degradation or non-specific accumulation requires drug delivery enabling technologies. Albumin is a natural transport protein with multiple ligand binding sites, cellular receptor engagement, and a long circulatory half-life due to interaction with the recycling neonatal Fc receptor. Exploitation of these properties promotes albumin as an attractive candidate for half-life extension and targeted intracellular delivery of drugs attached by covalent conjugation, genetic fusions, association or ligand-mediated association. This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.